The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells

Oncogene

Volumn 29, Issue 40, 2010, Pages 5523-5536

  Goncharenko Khaider, N ^a   Lane, D ^a   Matte, I ^a   Rancourt, C ^a   Piche A ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Bid; death receptors; ovarian carcinoma; PI3K Akt pathway; resistance; TRAIL

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 8; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BID; PROTEIN KINASE B; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; BID PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOCHONDRION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77957791204     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.288     Document Type: Article

References (48)

1. Asselin E, Mills GB, Tsang BK. (2001). XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61: 1862-1868.
2. Bast Jr RC, Hennessy B, Mills G. (2009). The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428.
3. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P et al. (2000). TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nature Cell Biol 2: 241-243.
4. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C et al. (2001). Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083.
5. Cheng L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403.
6. Cuello M, Coasts AO, Darko I, Ettenberg SA, Gardner GJ, Nau MM et al. (2004). N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochon-drial-dependent amplification loop in ovarian cancer cell lines. Cell Death & Differentiation 11: 527-541.
7. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. (2001). Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81: 380-390.
8. Dan HC, Sum M, Kaneko S, Feldman RI, Nicosia SV, Wang H-G et al. (2004). Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279: 5405-5412.
9. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
10. Del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. (1997). Interleukin-2-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689.
11. Desagher S, Ose-Sand A, Montessuit S, Magnenat E, Vilbois F, Hochmann A et al. (2001). Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase-8. Mol Cell 8: 601-611.
12. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. (1999). Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 18: 5242-5251.
13. Du K, Montminy M. (1998). CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273: 32377-32379.
14. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. (2003). P53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63: 7081-7088.
15. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. (1998). Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161: 2833-2840.
16. Hu L, Hoffmann J, Lu Y, Mill GB, Jaffe RB. (2002). Inhibition of phosphatidyl-inositol 3-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092.
17. Izeradjene K, Douglas L, Delaney A, Houghton JA. (2005). Casein Kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene 24: 2050-2058.
18. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DSC et al. (2009). XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460: 1035-1039.
19. Kandasamy K, Srivastava RK. (2002). Role of phosphatidylinositol 3-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 62: 4929-4937.
20. Kang YC, Kim KM, Lee KS, Namkoong S, Lee SJ, Han JA et al. (2004). Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differentiation 11: 1287-1298.
21. Kandel ES, Hay N. (1999). The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253: 210-229.
22. Kim KM, Lee YJ. (2005). Role of HER-2/neu signaling in sensitivity to tumor necrosis factor-related apoptosis-inducing ligand: enhancement of TRAIL-mediated apoptosis by amiloride. J Cell Biochem 96: 376-389.
23. Kim YH, Lee YJ. (2007). TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. J Cell Biochem 100: 998-1105.
24. Kim S-H, Ricci R, El-Deiry WS. (2008). Mcl-1: a gateway to TRAIL sensitization. Cancer Res 68: 2062-2064.
25. Kischkel FC, Hellbardt S, Merhamann I, Germer M, Pawlita M, Krammer PH et al. (1995). Cytotoxicity-dependent APO-1 (FAS/CD95)-associated proteins from a death-signaling complex (DISC) with the receptor. EMBO J 14: 5579-5588.
26. Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Gervais-Bird J, Madden R et al. (2008). Multiple alternative splicing markers for ovarian cancer. Cancer Res 68: 657-663.
27. Kruger A, Schmitz I, Krammer PH, Kirchhoff S. (2001). Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276: 20633-20640.
28. Lane D, Cartier A, L'Esperance S, Cote M, Rancourt C, Piche A. (2004). Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human ovarian carcinoma cells. Gynecol Oncol 93: 594-604.
29. Lane D, Cote M, Grondin R, Couture M-C, Piche A. (2006). Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Mol Cancer Ther 5: 509-521.
30. Lane D, Robert V, Grondin R, Rancourt C, Piche A. (2007). Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt in human ovarian carcinoma cells. Int J Cancer 121: 1227-1237.
31. Lane D, Cartier A, Rancourt C, Piche A. (2008). Cell adhesion confers protection against TRAIL killing by activating the phosphatidyl-inositol 3-kinase-dependent pathway in human ovarian carcinoma cells. Int J Gynecol Oncol 18: 670-676.
32. Lane D, Goncharenko-Khaider N, Rancourt C, Piche A. (2010). Ovarian cancer ascites protects from TRAIL-induced cell death through avb5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 29: 3519-3531.
33. Larribere L, Khaled M, Tartare-Deckert S, Busca R, Luciano F, Bille K et al. (2004). PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death & Differentiation 11: 1084-1091.
34. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P et al. (2002). Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8: 274-281.
35. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. (1998). Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490.
36. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikos PI, Hensley HH et al. (2007). RAD001 inhibits human ovarian cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13: 4261-4270.
37. Majewski N, Nogueira V, Robey RB, Hay N. (2004). Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cel Biol 24: 730-740.
38. Ndozangue-Touriguine O, Sebbagh M, Merino D, Micheau O, Bertoglio J, Berard J. (2008). A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 27: 6012-6022.
39. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. (2001). Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276: 10767-10774.
40. Newsom-Davis T, Prieske S, Walczak H. (2009). Is TRAIL the holy grail of cancer therapy? Apoptosis 14: 607-623.
41. Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M et al. (2000). Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 20: 407-416.
42. Panka DJ, Mamo T, Suhara T, Walsh K, Mier JW. (2001). Phosphatidyl-inositol 3-kianse/Akt activity regulates C-FLIP expression in tumor cells. J Biol Chem 276: 6893-6896.
43. Panner A, James CD, Berger MS, Pieper RO. (2005). mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 25: 8809-8823.
44. Siervo-Sassi RR, Marrangoni AM, Feng X, Winans M, Edwards RP, Lokshin A. (2003). Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Letters 190: 61-72.
45. Westfall SD, Skinner MK. (2005). Induction of phosphatidylinositol 3-kinase sesnitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol Cancer Ther 4: 1764-1771.
46. Yang X, Frasier M, Moll UT, Basak A, Tsang BK. (2006). Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66: 3126-3136.
47. Yap TA, Carden CP, Kaye SB. (2009). Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Reviews Cancer 9: 167-181.
48. Zhang L, Fang B. (2005). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237.